ANIP
ANI Pharmaceuticals, Inc. NASDAQ Listed May 5, 2000$79.49
-1.28%
vs $80.52
Mkt Cap $1.7B
52w Low $63.35
45.5% of range
52w High $98.81
50d MA $80.14
200d MA $83.06
P/E (TTM)
23.9x
EV/EBITDA
8.2x
P/B
3.0x
Debt/Equity
0.6x
ROE
14.5%
P/FCF
9.8x
RSI (14)
52.70
ATR (14)
$2.34
Beta
0.43
50d MA
$80.14
200d MA
$83.06
Avg Volume
377.0K
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
210 Main Street West · Baudette, MN 56623 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | 1.99 | 2.33 | +17.1% | 73.90 | +0.1% | +1.8% | +1.2% | +0.6% | -1.2% | -2.1% | — |
| Nov 7, 2025 | AMC | 1.74 | 2.04 | +17.2% | 90.43 | -3.2% | -1.7% | -0.4% | -1.4% | -3.1% | -0.6% | — |
| Aug 8, 2025 | AMC | 1.38 | 1.80 | +30.4% | 81.48 | +0.0% | +4.2% | +4.1% | +0.5% | +1.4% | -2.8% | — |
| May 9, 2025 | AMC | 1.37 | 1.70 | +24.1% | 66.30 | -0.0% | -6.0% | -0.5% | -2.6% | -1.4% | +0.8% | — |
| Feb 28, 2025 | AMC | 1.41 | 1.63 | +15.6% | 61.89 | -1.6% | -5.5% | +1.1% | +0.9% | +2.3% | -0.7% | — |
| Nov 8, 2024 | AMC | 1.09 | 1.34 | +22.9% | 61.44 | +0.1% | +0.5% | -1.2% | -1.9% | -1.5% | -4.0% | — |
| Aug 6, 2024 | AMC | 0.93 | 1.02 | +9.7% | 63.29 | -15.5% | -9.9% | -1.0% | +2.6% | +3.1% | -1.2% | — |
| May 10, 2024 | AMC | 0.98 | 1.21 | +23.5% | 68.05 | -0.5% | -1.0% | -1.9% | -1.8% | -1.6% | -3.7% | — |
| Feb 29, 2024 | AMC | 0.80 | 1.00 | +25.0% | 67.67 | +0.8% | -0.7% | -1.1% | -1.6% | +0.7% | +1.4% | — |
| Nov 8, 2023 | AMC | 0.76 | 1.27 | +67.1% | 54.32 | +1.2% | -3.8% | -0.2% | -1.0% | +3.0% | -1.7% | — |
| Aug 9, 2023 | AMC | 0.64 | 1.28 | +100.0% | 61.08 | +1.2% | -0.8% | +3.3% | -2.5% | +1.3% | -4.0% | — |
| May 8, 2023 | AMC | 0.34 | 1.17 | +244.1% | 42.58 | +2.9% | +4.3% | -1.4% | +0.4% | -5.2% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16 | Guggenheim | Maintains | Buy → Buy | — | $85.29 | $85.92 | +0.7% | -0.5% | +1.1% | -0.3% | -0.2% | -2.8% |
| Nov 10 | Guggenheim | Maintains | Buy → Buy | — | $90.43 | $87.58 | -3.2% | -1.7% | -0.4% | -1.4% | -3.1% | -0.6% |
| Oct 9 | Truist | Maintains | Hold → Hold | — | $91.65 | $91.65 | +0.0% | -0.9% | -1.1% | -1.3% | +0.1% | +1.5% |
| Sep 24 | JP Morgan | Maintains | Overweight → Overweight | — | $95.33 | $96.41 | +1.1% | -0.4% | -1.7% | -0.3% | -1.2% | -0.4% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.55 | $98.18 | +0.6% | -2.2% | +2.2% | -0.7% | -0.9% | -0.6% |
| Sep 8 | Guggenheim | Maintains | Buy → Buy | — | $95.35 | $95.85 | +0.5% | -0.2% | +3.4% | -1.0% | +1.3% | -1.0% |
| Aug 11 | Truist | Maintains | Hold → Hold | — | $81.48 | $81.50 | +0.0% | +4.2% | +4.1% | +0.5% | +1.4% | -2.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.01 | $77.86 | +12.8% | +18.1% | +4.2% | +4.1% | +0.5% | +1.4% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $66.30 | $66.28 | -0.0% | -6.0% | -0.5% | -2.6% | -1.4% | +0.8% |
| Apr 21 | Truist | Maintains | Hold → Hold | — | $69.21 | $69.16 | -0.1% | -1.7% | +1.4% | -0.8% | +1.9% | +0.3% |
| Apr 11 | Guggenheim | Maintains | Buy → Buy | — | $65.12 | $65.45 | +0.5% | +4.6% | +0.9% | +1.2% | -0.5% | +0.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.49 | $62.81 | +0.5% | +3.0% | -0.2% | +1.0% | -0.8% | -0.1% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $59.13 | $59.14 | +0.0% | +0.9% | +2.3% | -0.7% | -3.0% | +4.4% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.89 | $60.89 | -1.6% | -5.5% | +1.1% | +0.9% | +2.3% | -0.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.44 | $61.53 | +0.1% | +0.5% | -1.2% | -1.9% | -1.5% | -4.0% |
| Oct 22 | Truist | Maintains | Hold → Hold | — | $59.28 | $58.95 | -0.6% | +1.3% | -1.7% | +0.4% | -1.6% | -0.6% |
| Sep 18 | Raymond James | Maintains | Outperform → Outperform | — | $60.06 | $60.46 | +0.7% | +1.6% | -1.1% | -1.2% | +0.7% | -2.6% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.20 | $57.05 | +1.5% | +6.9% | +1.6% | -1.1% | -1.2% | +0.7% |
| Sep 11 | Truist | Downgrade | Buy → Hold | — | $55.48 | $53.51 | -3.6% | -2.1% | +3.4% | +4.2% | -3.9% | +6.9% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.29 | $53.51 | -15.5% | -9.9% | -1.0% | +2.6% | +3.1% | -1.2% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.19 | $65.29 | +1.7% | +2.0% | -3.7% | +0.9% | -0.4% | -1.3% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.05 | $67.69 | -0.5% | -1.0% | -1.9% | -1.8% | -1.6% | -3.7% |
| Apr 23 | Guggenheim | Maintains | Buy → Buy | — | $65.62 | $65.90 | +0.4% | +0.8% | -1.1% | -0.7% | +0.6% | +0.2% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $66.42 | $66.59 | +0.3% | -1.6% | +0.7% | +1.4% | +1.1% | -1.9% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.17 | $67.00 | -0.3% | -1.1% | -1.6% | +0.7% | +1.4% | +1.1% |
| Mar 1 | Truist | Maintains | Buy → Buy | — | $67.67 | $68.24 | +0.8% | -0.7% | -1.1% | -1.6% | +0.7% | +1.4% |
| Feb 16 | Truist | Maintains | Buy → Buy | — | $57.55 | $57.98 | +0.7% | +3.8% | -2.3% | -1.3% | +0.9% | +1.7% |
| Oct 19 | Guggenheim | Maintains | Buy → Buy | — | $57.39 | $57.21 | -0.3% | -0.1% | +0.2% | -1.0% | +2.1% | +1.6% |
| Sep 13 | Guggenheim | Maintains | Buy → Buy | — | $61.91 | $61.97 | +0.1% | +1.5% | +1.3% | -1.9% | -1.5% | -0.6% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.21 | $61.59 | +0.6% | +2.1% | +2.1% | -0.7% | +0.7% | -1.7% |
| Aug 21 | Truist | Maintains | Buy → Buy | — | $59.69 | $58.90 | -1.3% | +2.5% | +2.1% | +2.1% | -0.7% | +0.7% |
| Aug 10 | Guggenheim | Maintains | Buy → Buy | — | $61.08 | $61.83 | +1.2% | -0.8% | +3.3% | -2.5% | +1.3% | -4.0% |
| Jul 27 | Guggenheim | Maintains | Buy → Buy | — | $52.19 | $52.57 | +0.7% | -1.2% | +1.6% | +0.4% | -3.4% | +0.7% |
| Jul 21 | Truist | Maintains | Buy → Buy | — | $51.68 | $52.10 | +0.8% | +1.0% | +1.1% | -0.1% | -1.1% | -1.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | -1.4% | +0.4% | -5.2% | -1.9% |
| May 9 | Truist | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | -1.4% | +0.4% | -5.2% | -1.9% |
| May 9 | Raymond James | Maintains | Outperform → Outperform | — | $42.58 | $43.83 | +2.9% | +4.3% | -1.4% | +0.4% | -5.2% | -1.9% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | -1.4% | +0.4% | -5.2% | -1.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.86 | $40.84 | -0.0% | +0.4% | -1.1% | -1.3% | -0.6% | -1.0% |
| Mar 1 | Guggenheim | Maintains | Buy → Buy | — | $41.84 | $43.18 | +3.2% | +4.7% | +1.3% | +2.4% | -2.3% | -0.5% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.08 | $43.08 | +0.0% | -6.6% | +2.0% | +0.5% | -0.2% | +1.7% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.94 | $35.45 | +1.5% | +6.3% | +1.3% | -1.4% | -1.8% | -1.0% |
| Aug 9 | Raymond James | Maintains | Outperform → Outperform | — | $34.87 | $34.98 | +0.3% | -2.5% | +2.9% | +1.2% | +5.9% | +1.0% |
| Mar 16 | Raymond James | Maintains | Outperform → Outperform | — | $29.01 | $28.06 | -3.3% | -7.3% | +5.3% | -3.8% | -1.2% | +2.1% |
| Nov 2 | Truist | Maintains | Buy → Buy | — | $55.89 | $55.42 | -0.8% | +1.7% | -0.3% | -11.8% | +0.0% | +0.1% |
| Nov 2 | Raymond James | Maintains | Outperform → Outperform | — | $55.89 | $55.42 | -0.8% | +1.7% | -0.3% | -11.8% | +0.0% | +0.1% |
| May 10 | Raymond James | Maintains | Outperform → Outperform | — | $38.60 | $39.23 | +1.6% | -14.8% | +1.0% | +1.0% | -0.1% | +4.6% |
| Aug 3 | Raymond James | Maintains | Outperform → Outperform | — | $29.61 | $29.56 | -0.2% | +0.8% | +3.3% | +0.5% | -4.8% | +2.9% |
| May 8 | Raymond James | Maintains | Outperform → Outperform | — | $34.06 | $33.98 | -0.2% | +0.9% | +1.2% | -6.6% | -4.1% | -3.0% |
| May 7 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $36.96 | $40.62 | +9.9% | -7.8% | +0.9% | +1.2% | -6.6% | -4.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Cook MeredithOff | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $82.03 | $41K | 77,890 | +0.86% | — |
| Jun 8, 2026 | HAUGHEY THOMASDir | — | Sell | 2,000 | $80.88 | $162K | 38,878 | -0.24% | -2.99% |
| Jun 5, 2026 | CAREY STEPHEN P.Off | SVP & CFO | Sell | 3,312 | $80.00 | $265K | 180,393 | +0.80% | +0.86% |
| May 13, 2026 | Walsh Patrick DDir | — | Sell | 10,000 | $80.63 | $806K | 38,432 | -1.61% | +2.09% |
| May 13, 2026 | Cook MeredithOff | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39K | 78,390 | -1.61% | +2.09% |
| May 12, 2026 | Gutwerg OriOff | SVP, GENERICS | Sell | 2,772 | $79.50 | $220K | 78,696 | -1.61% | +2.09% |
| May 12, 2026 | Rowland Thomas AndrewOff | SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36K | 38,271 | -1.61% | +2.09% |
| May 11, 2026 | Walsh Patrick DDir | — | Sell | 3,973 | $80.75 | $321K | 48,432 | -1.61% | +2.09% |
| May 11, 2026 | Lalwani NikhilDir/Off | PRESIDENT & CEO | Sell | 55,000 | $77.57 | $4.3M | 349,889 | -1.61% | +2.09% |
8-K · 7.01
! Medium
ANI Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 13
8-K · 2.02
!! High
ANI Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
ANI Pharmaceuticals reported Q1 2026 earnings on May 8, 2026, though specific financial metrics require reviewing the full press release to assess investor impact.
May 8
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
ANIP's auditor switch from EisnerAmper to Ernst & Young suggests potential cost optimization or growth, but investors should verify if any audit disagreements prompted the change, which could signal hidden financial issues.
Apr 7
8-K · 7.01
! Medium
ANI Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
ANI Pharmaceuticals updated its investor presentation for use in ongoing investor and analyst meetings, providing stakeholders with current company information and financial guidance.
Mar 3
8-K
ANI Pharmaceuticals, Inc. -- 8-K Filing
ANI Pharmaceuticals reported strong Q4 2025 results and is strategically pivoting toward rare disease focus while maintaining its generics business, positioning for accelerated growth in 2026.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 823,064 | $63M | New | Mar 2026 |
| 2 | Soleus Capital Management, L.p. | 820,243 | $63M | Added | Mar 2026 |
| 3 | Millennium Management | 592,013 | $46M | Added | Mar 2026 |
| 4 | Morgan Stanley | 562,854 | $44M | Added | Dec 2025 |
| 5 | Arrowstreet Capital, Limited Partnership | 564,360 | $43M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 497,702 | $38M | Added | Mar 2026 |
| 7 | Tang Capital Management Llc | 481,437 | $38M | Added | Dec 2025 |
| 8 | Nuveen, Llc | 402,357 | $31M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 375,965 | $29M | New | Mar 2026 |
| 10 | Walleye Capital Llc | 366,150 | $28M | Added | Mar 2026 |
| 11 | Global Alpha Capital Management Ltd. | 361,240 | $28M | Reduced | Mar 2026 |
| 12 | William Blair Investment Management, Llc | 327,276 | $25M | Added | Mar 2026 |
| 13 | Invesco Ltd. | 324,349 | $25M | Added | Mar 2026 |
| 14 | Jones Hill Capital Lp | 318,591 | $24M | New | Mar 2026 |
| 15 | Nomura Holdings Inc | 237,225 | $18M | Added | Mar 2026 |
| 16 | Bank Of Montreal /can/ | 230,072 | $18M | Added | Mar 2026 |
| 17 | Teacher Retirement System Of Texas | 220,224 | $17M | Added | Mar 2026 |
| 18 | Royal Bank Of Canada | 213,919 | $16M | Reduced | Mar 2026 |
| 19 | D.e. Shaw & Co | 213,433 | $16M | Reduced | Mar 2026 |
| 20 | Jpmorgan Chase & Co | 220,166 | $16M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.69B
Enterprise Value
$1.71B
P/E (TTM)
23.94x
Forward P/E
8.76x
PEG Ratio
-0.05x
P/B
2.95x
P/S
1.91x
P/FCF
9.85x
EV/EBITDA
8.25x
Shares Out
21.2M
Financials (TTM)
Revenue
$883.4M
Net Income
$78.3M
EBITDA
$207.3M
Free Cash Flow
$171.4M
Op Cash Flow
$185.2M
EPS Basic
$3.50
EPS Diluted
$3.32
EPS Forward
$9.07
Gross Margin
51.0%
Op Margin
9.2%
Net Margin
8.9%
Balance Sheet
Total Assets
$1.44B
Total Liab.
$899.7M
Total Equity
$540.7M
Cash
$285.6M
LT Debt
$307.9M
Book Value/Sh
$26.96
Debt/Equity
0.60x
Current Ratio
2.71
Quick Ratio
2.19
Returns & Growth
ROE
14.5%
ROA
5.4%
ROIC
5.6%
Rev Growth YoY
+43.8%
EPS Growth YoY
+436.5%
Price Returns
2W
-1.3%
1M
-1.2%
3M
+6.2%
6M
-7.5%
12M
+33.7%
Technicals
52W High
$98.81
52W Low
$63.35
50d MA
$80.14
200d MA
$83.06
RSI (14)
52.70
ATR (14)
$2.34
Beta
0.43
Avg Volume
377K
Dividends
Div Rate
$0.06
Div Yield
0.1%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$124.00
High
$124.00
Low
$124.00
Median
$124.00
Data updated apr 24, 2026 6:11pm
· Source: financialmodelingprep.com